A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Open accessAbstract
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BRAF (BRAF(V600E)) depend on RAF-MEK-ERK signalling for tumour cell growth. RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistance to these agents remains a formidable challenge. Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here we carried out systematic gain-of-function resistance studies by expressing more than 15,500 genes individually in a BRAF(V600E) melanoma cell line treated with RAF, MEK, ERK or combined RAF-MEK inhibitors. These studies revealed a cyclic-AMP-dependent melanocytic signalling network not previously associated with drug resistance, including G-protein-coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein (CREB). Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAPK-pathway and histone-deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF-MEK-ERK inhibition, which may be overcome by combining signalling- and chromatin-directed therapeutics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
sgRNAs targeting ETS2 were significantly depleted in the CRISPR screen, consistent with a previous finding of its emergence as a resistance hit through a gain-of-function screen for resistance to MAPK pathway inhibitors in BRAF V600E melanoma.
“Notably, sgRNAs targeting ETS2 were significantly depleted, consistent with a previous finding of its emergence as a resistance hit through a gain-of-function screen for resistance to MAPK pathway inhibitors in BRAF V600E melanoma.49”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
Analysis of primary CRC samples from previously published cohorts revealed strong positive correlations between SMAD1 expression, FGFR1 and FGFR3 signaling activity, and Paneth cell signatures.
“Consistent with this, analysis of primary CRC samples from previously published cohorts49 revealed strong positive correlations between SMAD1 expression, FGFR1 and FGFR3 signaling activity, and Paneth cell signatures (Figures S6A and S6B).”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
The Abstract describes screens in melanoma cells, and the Experimental Methods describe expression profiling of melanoma cell lines. Searches for primary CRC cohorts, SMAD1, FGFR1/FGFR3 activity, and Paneth cell signatures found no passage addressing the claimed correlations. The cited paper therefore does not verify the claim in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measuredIn melanoma, core regulators of neural crest lineage, MITF and SOX10, regulate the emergence of distinct cell states associated with drug tolerance establishment after treatment.
“In melanoma, core regulators of neural crest lineage, MITF and SOX10, regulate the emergence of distinct cell states associated with drug tolerance establishment after treatment [61,82,83,84].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · see citing works
Self-citationPierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,712 · see citing works
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works
Self-citationGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · see citing works
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works
Self-citationImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,317 · see citing works
Self-citationRaf-1 activates MAP kinase-kinase
Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263 · see citing works
Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrı́msson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,092 · see citing works
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · see citing works
Self-citationThe Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product
Crews, C. M., Alessandrini, A., & Erikson, R. L. (1992) · Science · doi:10.1126/science.1411546 · Cited by 930 · see citing works
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C. M., Badalian, T. M., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 631 · see citing works
A public genome-scale lentiviral expression library of human ORFs
Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1638 · Cited by 570 · see citing works
Self-citationWu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 530 · see citing works
Ahn, S., Olive, M., Aggarwal, S., Krylov, D. Y., Ginty, D. D., & Vinson, C. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.967 · Cited by 502 · see citing works
Girotti, M. R., Pedersen, M., Sánchez‐Laorden, B. L., Virós, A., Turajlic, S., Niculescu‐Duvaz, D., Zambon, A., Sinclair, J., Hayes, A. J., Gore, M. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0386 · Cited by 380 · see citing works
Genetics of melanoma predisposition
Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 320 · see citing works
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L. M., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C. J., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304 · see citing works
Haq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K. T., PORTER, D. A., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 221 · see citing works
Self-citationWalton, K. M., Rehfuss, R. P., Chrivia, J. C., Lochner, J. E., & Goodman, R. H. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.4.1350057 · Cited by 218 · see citing works
Aronov, A. M., Tang, Q., Martínez-Botella, G., Bemis, G. W., Cao, J., Chen, G., Ewing, N. P., Ford, P. J., Germann, U. A., Green, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900630q · Cited by 146 · see citing works
An Oncogenic Role for <i>ETV1</i> in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115 · see citing works
Self-citationTpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase.
Patriotis, C., Makris, A. M., Chernoff, J., & Tsichlis, P. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9755 · Cited by 113 · see citing works
Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 106 · see citing works
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Yokoyama, S., Feige, E., Poling, L. L., Levy, C., Widlund, H. R., Khaled, M., Kung, A. L., & Fisher, D. E. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00480.x · Cited by 104 · see citing works
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood, K. C., Konieczkowski, D. J., Johannessen, C. M., Boehm, J. S., Tamayo, P., Botvinnik, O. B., Mesirov, J. P., Hahn, W. C., Root, D. E., Garraway, L. A., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002612 · Cited by 36 · see citing works
Self-citationCharacterization of MEK1 phosphorylation by the v-Mos protein.
Pham, C. D., Arlinghaus, R. B., Zheng, C., Guan, K., & Singh, B. (1995) · PubMed · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · see citing works
Self-citationNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · see citing works
Self-citationGenome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · see citing works
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770 · see citing works
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463 · see citing works
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,243 · see citing works
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works
Self-citationTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 828 · see citing works
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771 · see citing works
Self-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 759 · see citing works
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639 · see citing works
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 596 · see citing works
Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D., Sturm, D., Hermann, C., Segura‐Wang, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.001 · Cited by 572 · see citing works
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · see citing works
Self-citationA Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 526 · see citing works
Self-citationTherapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 485 · see citing works
Lauss, M., Donia, M., Harbst, K., Andersen, R. S., Mitra, S., Rosengren, F., Salim, M., Vallon‐Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 481 · see citing works
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · see citing works
Self-citationCombining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works
Am I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452 · see citing works
The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
Lo, J. A., & Fisher, D. E. (2014) · Science · doi:10.1126/science.1253735 · Cited by 426 · see citing works
Tumour heterogeneity and the evolution of polyclonal drug resistance
Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 417 · see citing works
Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood
Joung, J., Engreitz, J., Konermann, S., Abudayyeh, O. O., Verdine, V. K., Aguet, F., Gootenberg, J. S., Sanjana, N. E., Wright, J. B., Fulco, C. P., et al. (2017) · Nature · doi:10.1038/nature23451 · Cited by 417 · see citing works
The melanocyte lineage in development and disease
Mort, R. L., Jackson, I. J., & Patton, E. E. (2015) · Development · doi:10.1242/dev.106567 · Cited by 416 · see citing works
Anti-Inflammatory Drugs as Anticancer Agents
Zappavigna, S., Cossu, A. M., Grimaldi, A., Bocchetti, M., Ferraro, G. A., Nicoletti, G. F., Filosa, R., & Caraglia, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072605 · Cited by 401 · see citing works
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · see citing works
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361 · see citing works
Self-citationToward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 329 · see citing works
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., de Oliveira, R. L., Huijberts, S. C. F. A., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A. R., Song, J., Zevenhoven, J., Vries, G. T. L.-D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 321 · see citing works
MITF in melanoma: mechanisms behind its expression and activity
Hartman, M. L., & Czyż, M. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 319 · see citing works
Codon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271 · see citing works
Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltrán, A. S., Duncan, J. S., Angus, S. P., Collins, K. A. L., Granger, D. A., Reuther, R. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.037 · Cited by 270 · see citing works
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258 · see citing works
Self-citationBig data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254 · see citing works
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 239 · see citing works
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 239 · see citing works
Self-citationTargeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gómez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I. P., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 239 · see citing works
Falletta, P., Sánchez‐del‐Campo, L., Chauhan, J. S., Effern, M., Kenyon, A., Kershaw, C. J., Siddaway, R., Lisle, R., Freter, R., Daniels, M. J., et al. (2017) · Genes & Development · doi:10.1101/gad.290940.116 · Cited by 239 · see citing works
Germann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M. R., Boucher, D. M., Sorrell, D. A., Martínez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 234 · see citing works
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 228 · see citing works
Self-citationRiesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Sirokay, J. D., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 223 · see citing works
Smith, M. P., Sánchez‐Laorden, B. L., O’Brien, K., Brunton, H., Ferguson, J., Young, H. L., Dhomen, N. S., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1007 · Cited by 222 · see citing works
Self-citationPathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 219 · see citing works
Self-citationWellbrock, C., & Arozarena, I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12370 · Cited by 218 · see citing works
What turns CREB on? And off? And why does it matter?
Steven, A., Friedrich, M., Jank, P., Heimer, N., Budczies, J., Denkert, C., & Seliger, B. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03525-8 · Cited by 214 · see citing works
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 211 · see citing works
High-throughput Phenotyping of Lung Cancer Somatic Mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C. R., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M. B., Hogstrom, L. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 207 · see citing works
Self-citationThe journey from melanocytes to melanoma
Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 202 · see citing works
Genetic and epigenetic aspects of breast cancer progression and therapy.
Byler, S., Goldgar, S., Heerboth, S., Leary, M., Housman, G., Moulton, K. L., & Sarkar, S. (2014) · PubMed · Cited by 199 · see citing works
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 199 · see citing works
Delving deeper into resistance
Seton-Rogers, S. E. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3653 · Cited by 194 · see citing works
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 183 · see citing works
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 181 · see citing works
Wu, V. H., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 177 · see citing works
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174 · see citing works
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Allen, E. M. V., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 171 · see citing works
Self-citationMao, P., Cohen, O., Kowalski, K. J., Kusiel, J. G., Buendia-Buendia, J. E., Cuoco, M. S., Exman, P., Wander, S. A., Waks, A. G., Nayar, U., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3958 · Cited by 171 · see citing works
Self-citationPAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N. L., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 168 · see citing works
Self-citationThe RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke‐Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 167 · see citing works
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 163 · see citing works
Self-citationKEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160 · see citing works
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants
Brenan, L., Andreev, A., Cohen, O., Pantel, S., Kamburov, A., Cacchiarelli, D., Persky, N. S., Zhu, C., Bagul, M., Goetz, E. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.061 · Cited by 159 · see citing works
Self-citationcAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Zhang, H., Liu, Y., Liu, J., Chen, J., Wang, J., Hua, H. M., & Jiang, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01524-x · Cited by 149 · see citing works
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Hsiao, J. J., & Fisher, D. E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.019 · Cited by 148 · see citing works
cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach
Ahmed, M. B., Alghamdi, A. A. A., Islam, S. U., Lee, J., & Lee, Y. S. (2022) · Cells · doi:10.3390/cells11132020 · Cited by 148 · see citing works
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Arang, N., & Gutkind, J. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.14017 · Cited by 147 · see citing works
Palmer, A. C., Chidley, C., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.50036 · Cited by 136 · see citing works
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 134 · see citing works
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Le, X., Antony, R., Razavi, P., Treacy, D. J., Luo, F., Ghandi, M., Castel, P., Scaltriti, M., Baselga, J. M., & Garraway, L. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0305 · Cited by 132 · see citing works
Self-citationSteven, A., & Seliger, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7721 · Cited by 130 · see citing works
ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Richard, G., Dalle, S., Monet, M., Plaschka, M., Boespflug, A. M., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 129 · see citing works
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 128 · see citing works
Epithelial‐to‐mesenchymal‐like transition events in melanoma
Pedri, D., Karras, P., Landeloos, E., Marine, J., & Rambow, F. (2021) · FEBS Journal · doi:10.1111/febs.16021 · Cited by 126 · see citing works
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 125 · see citing works
Self-citationOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 123 · see citing works
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 121 · see citing works
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 117 · see citing works
Cyclic AMP (cAMP) signaling in melanocytes and melanoma
Rodríguez, C. I., & Setaluri, V. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.003 · Cited by 112 · see citing works
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 111 · see citing works
Predicting and affecting response to cancer therapy based on pathway-level biomarkers
Ben‐Hamo, R., Berger, A. J., Gavert, N. S., Miller, M. L., Pines, G., Oren, R., Pikarsky, E., Benes, C. H., Neuman, T., Zwang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17090-y · Cited by 109 · see citing works
Mechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 108 · see citing works
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107 · see citing works
Self-citationInhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
Salton, M., Kasprzak, W. K., Voss, T. C., Shapiro, B. A., Poulikakos, P. I., & Misteli, T. (2015) · Nature Communications · doi:10.1038/ncomms8103 · Cited by 107 · see citing works
Focus on cutaneous and uveal melanoma specificitiesPreprint
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 107 · see citing works
Daniel, P. M., Filiz, G., Brown, D. V., Hollande, F., Gonzales, M. F., D’Abaco, G. M., Papalexis, N., Phillips, W. A., Malaterre, J., Ramsay, R. G., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.21 · Cited by 105 · see citing works
Terai, H., Kitajima, S., Potter, D. S., Matsui, Y., Quiceno, L. G., Chen, T., Kim, T. J., Rusan, M., Thai, T. C., Piccioni, F., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1904 · Cited by 105 · see citing works
Self-citation“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 104 · see citing works
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S.-C., Kim, S. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3751 · Cited by 103 · see citing works
Rose, A. A. N., Biondini, M., Curiel, R. E., & Siegel, P. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.010 · Cited by 101 · see citing works
Li, Y., Cheng, H. S., Chng, W. J., & Tergaonkar, V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611106113 · Cited by 100 · see citing works
Resistance to Molecularly Targeted Therapies in Melanoma
Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021) · Cancers · doi:10.3390/cancers13051115 · Cited by 100 · see citing works
Corre, S., Tardif, N., Mouchet, N., Leclair, H. M., Boussemart, L., Gautron, A., Bachelot, L., Perrot, A., Soshilov, A. A., Rogiers, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06951-2 · Cited by 98 · see citing works
Faião‐Flores, F., Alves-Fernandes, D. K., Pennacchi, P. C., Sandri, S., Vicente, A. L. S. A., Scapulatempo‐Neto, C., Vazquez, V. D. L., Reis, R. M., Chauhan, J. S., Goding, C. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.348 · Cited by 98 · see citing works
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95 · see citing works
Self-citationUnderstanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 93 · see citing works
MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.012 · Cited by 93 · see citing works
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 93 · see citing works
Iniguez, A. B., Alexe, G., Wang, E. J., Roti, G., Patel, S., Chen, L., Kitara, S., Conway, A. S., Robichaud, A. L., Stolte, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.005 · Cited by 90 · see citing works
Self-citation
- Authors
- Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Venue
- Nature
- Published
- 2013-11-03
- Volume
- 504
- Issue
- 7478
- Pages
- 138-142
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4098832
- OpenAlex
- W2159220884
- Cited by
- 452
- References
- 28
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 22 · 2022: 27 · 2021: 32 · 2020: 49 · 2019: 45 · 2018: 36 · 2017: 57 · 2016: 48 · 2015: 41 · 2014: 47 · 2013: 4
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG006093, U01HG006492)
- National Cancer Institute (P50-CA-93683, R33CA155554, P50CA093683, P01CA163222)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- BRAF V600E mutation, cAMP signaling, CREB, MITF, melanocyte lineage, RAF inhibitors, MEK inhibitors, histone deacetylase inhibitors, G protein-coupled receptors, adenylate cyclase, c-fos, drug resistance mechanisms, therapeutic target
- MeSH terms
- Cyclic AMP, Antineoplastic Agents, Humans, Melanocytes, Melanoma, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Lineage, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, CREB-Binding Protein, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
